TrkA fusion protein was also discovered in a case of liver metastasis of CRC, and application of Entrectinib, a selective Trk inhibitor, managed to achieve clinical partial response (Sartore-Bianchi et al., 2016). This evidence concerns the gene NTRK1 and colorectal carcinoma.